{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T23:45:50Z","timestamp":1789343150801,"version":"build-2803163510"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,8,12]],"date-time":"2024-08-12T00:00:00Z","timestamp":1723420800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,8,12]],"date-time":"2024-08-12T00:00:00Z","timestamp":1723420800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100004699","name":"Chung Shan Medical University Hospital","doi-asserted-by":"publisher","award":["CSH-2022-A-001"],"award-info":[{"award-number":["CSH-2022-A-001"]}],"id":[{"id":"10.13039\/501100004699","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004699","name":"Chung Shan Medical University Hospital","doi-asserted-by":"publisher","award":["CSH-2021-D-001"],"award-info":[{"award-number":["CSH-2021-D-001"]}],"id":[{"id":"10.13039\/501100004699","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"DOI":"10.1007\/s10238-024-01448-3","type":"journal-article","created":{"date-parts":[[2024,8,12]],"date-time":"2024-08-12T12:02:32Z","timestamp":1723464152000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Abatacept versus tumor necrosis factor inhibitors on mortality and medical utilizations in the treatment of rheumatoid arthritis associated interstitial lung disease: a large-scale real-world retrospective cohort study"],"prefix":"10.1007","volume":"24","author":[{"given":"Po-Cheng","family":"Shih","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chih-Cheng","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing-Hua","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiow-Ing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang-Yang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James Cheng Chung","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,12]]},"reference":[{"issue":"10","key":"1448_CR1","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1136\/annrheumdis-2017-211138","volume":"76","author":"C Hyldgaard","year":"2017","unstructured":"Hyldgaard C, Hilberg O, Pedersen AB, et al. A population-based cohort study of rheumatoid arthritis-associated interstitial lung disease: comorbidity and mortality. Ann Rheum Dis. 2017;76(10):1700\u20136.","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"1448_CR2","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1016\/j.resinv.2016.03.001","volume":"54","author":"T Nakashita","year":"2016","unstructured":"Nakashita T, Ando K, Takahashi K, et al. Possible effect of abatacept on the progression of interstitial lung disease in rheumatoid arthritis patients. Respir Investig. 2016;54(5):376\u20139.","journal-title":"Respir Investig"},{"issue":"7","key":"1448_CR3","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.3390\/biomedicines10071480","volume":"10","author":"N Mena-V\u00e1zquez","year":"2022","unstructured":"Mena-V\u00e1zquez N, Rojas-Gimenez M, Fuego-Varela C, et al. Safety and effectiveness of abatacept in a prospective cohort of patients with rheumatoid arthritis-associated interstitial lung disease. Biomedicines. 2022;10(7):1480.","journal-title":"Biomedicines"},{"issue":"6","key":"1448_CR4","doi-asserted-by":"publisher","first-page":"102830","DOI":"10.1016\/j.autrev.2021.102830","volume":"20","author":"EF Vicente-Rabaneda","year":"2021","unstructured":"Vicente-Rabaneda EF, Atienza-Mateo B, Blanco R, et al. Efficacy and safety of abatacept in interstitial lung disease of rheumatoid arthritis: a systematic literature review. Autoimmun Rev. 2021;20(6):102830.","journal-title":"Autoimmun Rev"},{"issue":"1","key":"1448_CR5","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1007\/s12016-013-8359-x","volume":"47","author":"CB Chighizola","year":"2014","unstructured":"Chighizola CB, Favalli EG, Meroni PL. Novel mechanisms of action of the biologicals in rheumatic diseases. Clin Rev Allergy Immunol. 2014;47(1):6\u201316.","journal-title":"Clin Rev Allergy Immunol"},{"issue":"1","key":"1448_CR6","doi-asserted-by":"publisher","first-page":"32","DOI":"10.3899\/jrheum.170007","volume":"45","author":"LR Harrold","year":"2018","unstructured":"Harrold LR, Litman HJ, Connolly SE, et al. Effect of anticitrullinated protein antibody status on response to abatacept or antitumor necrosis factor-\u03b1 therapy in patients with rheumatoid arthritis: a US national observational study. J Rheumatol. 2018;45(1):32\u20139.","journal-title":"J Rheumatol"},{"issue":"3","key":"1448_CR7","doi-asserted-by":"publisher","first-page":"e040465","DOI":"10.1136\/bmjopen-2020-040465","volume":"11","author":"H Kamiya","year":"2021","unstructured":"Kamiya H, Panlaqui OM. Systematic review and meta-analysis of the risk of rheumatoid arthritis-associated interstitial lung disease related to anti-cyclic citrullinated peptide (CCP) antibody. BMJ Open. 2021;11(3):e040465.","journal-title":"BMJ Open"},{"key":"1448_CR8","doi-asserted-by":"publisher","first-page":"1265355","DOI":"10.3389\/fmed.2023.1265355","volume":"10","author":"D Chai","year":"2023","unstructured":"Chai D, Sun D, Wang Y, et al. Progression of radiographic fibrosis in rheumatoid arthritis-associated interstitial lung disease. Front Med. 2023;10:1265355.","journal-title":"Front Med."},{"issue":"5","key":"1448_CR9","doi-asserted-by":"publisher","first-page":"103056","DOI":"10.1016\/j.autrev.2022.103056","volume":"21","author":"M Akiyama","year":"2022","unstructured":"Akiyama M, Kaneko Y. Pathogenesis, clinical features, and treatment strategy for rheumatoid arthritis-associated interstitial lung disease. Autoimmun Rev. 2022;21(5):103056.","journal-title":"Autoimmun Rev"},{"issue":"3","key":"1448_CR10","doi-asserted-by":"publisher","first-page":"e003038","DOI":"10.1136\/rmdopen-2023-003038","volume":"9","author":"J-J Tsai","year":"2023","unstructured":"Tsai J-J, Liu L-T, Chen C-H, et al. COVID-19 outcomes in patients with rheumatoid arthritis with biologic or targeted synthetic DMARDs. RMD Open. 2023;9(3):e003038.","journal-title":"RMD Open"},{"key":"1448_CR11","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s10557-022-07387-z","volume":"38","author":"A Cordova Sanchez","year":"2022","unstructured":"Cordova Sanchez A, Khokhar F, Olonoff DA, et al. Hydroxychloroquine and cardiovascular events in patients with rheumatoid arthritis. Cardiovasc Drugs Therapy. 2022;38:297\u2013304.","journal-title":"Cardiovasc Drugs Therapy."},{"key":"1448_CR12","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/s40674-020-00160-z","volume":"6","author":"S Huang","year":"2020","unstructured":"Huang S, Kronzer VL, Dellaripa PF, et al. Rheumatoid arthritis\u2013associated interstitial lung disease: current update on prevalence, risk factors, and pharmacologic treatment. Curr Treat Options Rheumatol. 2020;6:337\u201353.","journal-title":"Curr Treat Options Rheumatol"},{"issue":"3","key":"1448_CR13","doi-asserted-by":"publisher","first-page":"e007393","DOI":"10.1161\/JAHA.117.007393","volume":"7","author":"EH Kang","year":"2018","unstructured":"Kang EH, Jin Y, Brill G, et al. Comparative cardiovascular risk of abatacept and tumor necrosis factor inhibitors in patients with rheumatoid arthritis with and without diabetes mellitus: a multidatabase cohort study. J Am Heart Assoc. 2018;7(3):e007393.","journal-title":"J Am Heart Assoc"},{"issue":"9","key":"1448_CR14","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.3899\/jrheum.170926","volume":"45","author":"Y Jin","year":"2018","unstructured":"Jin Y, Kang EH, Brill G, et al. Cardiovascular (CV) risk after initiation of abatacept versus TNF inhibitors in rheumatoid arthritis patients with and without baseline CV disease. J Rheumatol. 2018;45(9):1240\u20138.","journal-title":"J Rheumatol"},{"issue":"11","key":"1448_CR15","doi-asserted-by":"publisher","first-page":"2837","DOI":"10.4049\/jimmunol.1900473","volume":"203","author":"EK Wu","year":"2019","unstructured":"Wu EK, Henkes ZI, McGowan B, et al. TNF-induced interstitial lung disease in a murine arthritis model: accumulation of activated monocytes, conventional dendritic cells, and CD21+\/CD23\u2212 B cell follicles is prevented with anti-TNF therapy. J Immunol. 2019;203(11):2837\u201349.","journal-title":"J Immunol"},{"issue":"19","key":"1448_CR16","doi-asserted-by":"publisher","first-page":"14509","DOI":"10.3390\/ijms241914509","volume":"24","author":"Y Kim","year":"2023","unstructured":"Kim Y, Yang H-I, Kim K-S. Etiology and pathogenesis of rheumatoid arthritis-interstitial lung disease. Int J Mol Sci. 2023;24(19):14509.","journal-title":"Int J Mol Sci"},{"key":"1448_CR17","doi-asserted-by":"publisher","first-page":"103478","DOI":"10.1016\/j.autrev.2023.103478","volume":"23","author":"F Atzeni","year":"2023","unstructured":"Atzeni F, Cacciapaglia F, Galloways J, et al. Effects of cytotoxic T-lymphocyte-associated protein 4 compared to TNF inhibitors on lipid profile: results from an observational multicentre rheumatoid arthritis cohort. Autoimmun Rev. 2023;23:103478.","journal-title":"Autoimmun Rev."},{"issue":"3","key":"1448_CR18","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1111\/1756-185X.14550","volume":"26","author":"H Azadeh","year":"2023","unstructured":"Azadeh H. Association between disease-modifying antirheumatic drugs and bone turnover biomarkers. Int J Rheum Dis. 2023;26(3):437\u201345.","journal-title":"Int J Rheum Dis"},{"issue":"2","key":"1448_CR19","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1007\/s40744-021-00310-2","volume":"8","author":"LR Harrold","year":"2021","unstructured":"Harrold LR, Bryson J, Lehman T, et al. Association between baseline anti-cyclic citrullinated peptide antibodies and 6-month clinical response following abatacept or TNF inhibitor treatment: a real-world analysis of biologic-experienced patients with RA. Rheumatol Ther. 2021;8(2):937\u201353.","journal-title":"Rheumatol Ther"},{"issue":"1","key":"1448_CR20","doi-asserted-by":"publisher","first-page":"e000345","DOI":"10.1136\/rmdopen-2016-000345","volume":"3","author":"R Alten","year":"2017","unstructured":"Alten R, N\u00fc\u00dflein HG, Mariette X, et al. Baseline autoantibodies preferentially impact abatacept efficacy in patients with rheumatoid arthritis who are biologic na\u00efve: 6-month results from a real-world, international, prospective study. RMD Open. 2017;3(1):e000345.","journal-title":"RMD Open"},{"issue":"4","key":"1448_CR21","doi-asserted-by":"publisher","first-page":"666","DOI":"10.3899\/jrheum.130905","volume":"41","author":"M Scarsi","year":"2014","unstructured":"Scarsi M, Paolini L, Ricotta D, et al. Abatacept reduces levels of switched memory B cells, autoantibodies, and immunoglobulins in patients with rheumatoid arthritis. J Rheumatol. 2014;41(4):666\u201372.","journal-title":"J Rheumatol"},{"key":"1448_CR22","doi-asserted-by":"crossref","unstructured":"Chen N, Diao C-Y, Gao J, et al., editors. Risk factors for the progression of rheumatoid arthritis-related interstitial lung disease: clinical features, biomarkers, and treatment options. In: Seminars in arthritis and rheumatism; 2022: Elsevier.","DOI":"10.1016\/j.semarthrit.2022.152004"},{"issue":"4","key":"1448_CR23","doi-asserted-by":"publisher","first-page":"874","DOI":"10.3390\/jcm10040874","volume":"10","author":"N Mena-V\u00e1zquez","year":"2021","unstructured":"Mena-V\u00e1zquez N, Rojas-Gimenez M, Romero-Barco CM, et al. Predictors of progression and mortality in patients with prevalent rheumatoid arthritis and interstitial lung disease: a prospective cohort study. J Clin Med. 2021;10(4):874.","journal-title":"J Clin Med"},{"issue":"7","key":"1448_CR24","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1111\/1756-185X.14351","volume":"25","author":"L Liu","year":"2022","unstructured":"Liu L, Fang C, Sun B, et al. Predictors of progression in rheumatoid arthritis-associated interstitial lung disease: a single-center retrospective study from China. Int J Rheum Dis. 2022;25(7):795\u2013802.","journal-title":"Int J Rheum Dis"},{"issue":"1","key":"1448_CR25","doi-asserted-by":"publisher","first-page":"19717","DOI":"10.1038\/s41598-020-76842-4","volume":"10","author":"D Kida","year":"2020","unstructured":"Kida D, Takahashi N, Kaneko A, et al. A retrospective analysis of the relationship between anti-cyclic citrullinated peptide antibody and the effectiveness of abatacept in rheumatoid arthritis patients. Sci Rep. 2020;10(1):19717.","journal-title":"Sci Rep"},{"issue":"3","key":"1448_CR26","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1620\/tjem.250.153","volume":"250","author":"S Okazaki","year":"2020","unstructured":"Okazaki S, Watanabe R, Harigae H, et al. Better retention of abatacept is associated with high rheumatoid factor: a five-year follow-up study of patients with rheumatoid arthritis. Tohoku J Exp Med. 2020;250(3):153\u20139.","journal-title":"Tohoku J Exp Med"},{"issue":"5","key":"1448_CR27","doi-asserted-by":"publisher","first-page":"e0216624","DOI":"10.1371\/journal.pone.0216624","volume":"14","author":"K Ebina","year":"2019","unstructured":"Ebina K, Hashimoto M, Yamamoto W, et al. Drug tolerability and reasons for discontinuation of seven biologics in elderly patients with rheumatoid arthritis\u2014the ANSWER cohort study. PLoS ONE. 2019;14(5):e0216624.","journal-title":"PLoS ONE"},{"issue":"1","key":"1448_CR28","doi-asserted-by":"publisher","first-page":"e28501","DOI":"10.1097\/MD.0000000000028501","volume":"101","author":"K-H Yu","year":"2022","unstructured":"Yu K-H, Chen H-H, Cheng T-T, et al. Consensus recommendations on managing the selected comorbidities including cardiovascular disease, osteoporosis, and interstitial lung disease in rheumatoid arthritis. Medicine. 2022;101(1):e28501.","journal-title":"Medicine."},{"key":"1448_CR29","doi-asserted-by":"crossref","unstructured":"Suissa S, Hudson M, Dell\u2019Aniello S, et al., editors. Comparative safety of abatacept in rheumatoid arthritis with COPD: a real-world population-based observational study. In: Seminars in arthritis and rheumatism; 2019: Elsevier.","DOI":"10.1136\/annrheumdis-2019-eular.1607"},{"issue":"1","key":"1448_CR30","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1002\/acr.23824","volume":"72","author":"SK Chen","year":"2020","unstructured":"Chen SK, Liao KP, Liu J, et al. Risk of hospitalized infection and initiation of abatacept versus tumor necrosis factor inhibitors among patients with rheumatoid arthritis: a propensity score\u2013matched cohort study. Arthritis Care Res. 2020;72(1):9\u201317.","journal-title":"Arthritis Care Res"},{"key":"1448_CR31","doi-asserted-by":"crossref","unstructured":"Simon TA, Suissa S, Skovron ML, et al., editors. Infection outcomes in patients with rheumatoid arthritis treated with abatacept and other disease-modifying antirheumatic drugs: results from a 10-year international post-marketing study. In: Seminars in arthritis and rheumatism; 2024: Elsevier.","DOI":"10.1016\/j.semarthrit.2023.152240"},{"issue":"2","key":"1448_CR32","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1093\/mr\/road031","volume":"34","author":"M Harigai","year":"2024","unstructured":"Harigai M, Fujii T, Sakai R, et al. Risk of hospitalized infections in older elderly patients with rheumatoid arthritis treated with tocilizumab or other biological\/targeted synthetic disease-modifying antirheumatic drugs: evaluation of data from a Japanese claims database. Mod Rheumatol. 2024;34(2):287\u201396.","journal-title":"Mod Rheumatol"},{"issue":"6","key":"1448_CR33","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1136\/ard.2009.120626","volume":"69","author":"W Dixon","year":"2010","unstructured":"Dixon W, Hyrich K, Watson K, et al. Influence of anti-TNF therapy on mortality in patients with rheumatoid arthritis-associated interstitial lung disease: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis. 2010;69(6):1086\u201391.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"1448_CR34","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1002\/art.27405","volume":"62","author":"T Bongartz","year":"2010","unstructured":"Bongartz T, Nannini C, Medina-Velasquez YF, et al. Incidence and mortality of interstitial lung disease in rheumatoid arthritis: a population-based study. Arthritis Rheum. 2010;62(6):1583\u201391.","journal-title":"Arthritis Rheum"},{"issue":"2","key":"1448_CR35","doi-asserted-by":"publisher","first-page":"e003789","DOI":"10.1136\/rmdopen-2023-003789","volume":"10","author":"T Rudi","year":"2024","unstructured":"Rudi T, Zietemann V, Meissner Y, et al. Impact of DMARD treatment and systemic inflammation on all-cause mortality in patients with rheumatoid arthritis and interstitial lung disease: a cohort study from the German RABBIT register. RMD Open. 2024;10(2):e003789.","journal-title":"RMD Open"},{"issue":"4","key":"1448_CR36","doi-asserted-by":"publisher","first-page":"1882","DOI":"10.1093\/rheumatology\/keaa577","volume":"60","author":"CA Kelly","year":"2021","unstructured":"Kelly CA, Nisar M, Arthanari S, et al. Rheumatoid arthritis related interstitial lung disease\u2013improving outcomes over 25 years: a large multicentre UK study. Rheumatology. 2021;60(4):1882\u201390.","journal-title":"Rheumatology"},{"issue":"3","key":"1448_CR37","doi-asserted-by":"publisher","first-page":"e233640","DOI":"10.1001\/jamanetworkopen.2023.3640","volume":"6","author":"MC Baker","year":"2023","unstructured":"Baker MC, Liu Y, Lu R, et al. Incidence of interstitial lung disease in patients with rheumatoid arthritis treated with biologic and targeted synthetic disease-modifying antirheumatic drugs. JAMA Netw Open. 2023;6(3):e233640.","journal-title":"JAMA Netw Open."},{"key":"1448_CR38","doi-asserted-by":"crossref","unstructured":"Kang EH, Jin Y, Desai RJ, et al., editors. Risk of exacerbation of pulmonary comorbidities in patients with rheumatoid arthritis after initiation of abatacept versus TNF inhibitors: a cohort study. In: Seminars in arthritis and rheumatism; 2020: Elsevier.","DOI":"10.1016\/j.semarthrit.2019.11.010"},{"key":"1448_CR39","unstructured":"Fern\u00e1ndez-D\u00edaz C, Loricera J, Casta\u00f1eda S, et al., editors. Abatacept in patients with rheumatoid arthritis and interstitial lung disease: A national multicenter study of 63 patients. Seminars in arthritis and rheumatism; 2018: Elsevier."},{"issue":"1","key":"1448_CR40","doi-asserted-by":"publisher","first-page":"277","DOI":"10.3390\/jcm9010277","volume":"9","author":"G Cassone","year":"2020","unstructured":"Cassone G, Manfredi A, Atzeni F, et al. Safety of abatacept in Italian patients with rheumatoid arthritis and interstitial lung disease: a multicenter retrospective study. J Clin Med. 2020;9(1):277.","journal-title":"J Clin Med"},{"issue":"12","key":"1448_CR41","doi-asserted-by":"publisher","first-page":"3906","DOI":"10.1093\/rheumatology\/keaa621","volume":"59","author":"C Fern\u00e1ndez-D\u00edaz","year":"2020","unstructured":"Fern\u00e1ndez-D\u00edaz C, Casta\u00f1eda S, Melero-Gonz\u00e1lez RB, et al. Abatacept in interstitial lung disease associated with rheumatoid arthritis: national multicenter study of 263 patients. Rheumatology. 2020;59(12):3906\u201316.","journal-title":"Rheumatology"},{"key":"1448_CR42","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.ejim.2023.08.025","volume":"119","author":"B Atienza-Mateo","year":"2024","unstructured":"Atienza-Mateo B, Fern\u00e1ndez-D\u00edaz C, Vicente-Rabaneda EF, et al. Abatacept in usual and in non-specific interstitial pneumonia associated with rheumatoid arthritis. Eur J Intern Med. 2024;119:118\u201324.","journal-title":"Eur J Intern Med"},{"key":"1448_CR43","volume-title":"POS0599 rheumatoid arthritis-progressive interstitial lung disease with abatacept: data from a large national multicenter cohort","author":"A Serrano-Combarro","year":"2024","unstructured":"Serrano-Combarro A, Atienza-Mateo B, Paino LI, et al. POS0599 rheumatoid arthritis-progressive interstitial lung disease with abatacept: data from a large national multicenter cohort. BMJ Publishing Group Ltd; 2024."}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-024-01448-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10238-024-01448-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-024-01448-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,30]],"date-time":"2024-11-30T17:26:24Z","timestamp":1732987584000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10238-024-01448-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,12]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1448"],"URL":"https:\/\/doi.org\/10.1007\/s10238-024-01448-3","relation":{},"ISSN":["1591-9528"],"issn-type":[{"value":"1591-9528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,12]]},"assertion":[{"value":"24 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was approved with the approval of the Institutional Review Board of the Chung Shan Medical University Hospital (CSMUH No CS2-21105). The TriNetX database provides a platform for access to de-identified data, ensuring compliance with privacy and ethical standards. Thus, individual patient consent was not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The TriNetX database provides a platform for access to de-identified data, ensuring compliance with privacy and ethical standards. Thus, individual patient consent was not required.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"186"}}